As of Apr 21
| +0.235 / +1.71%|
The 10 analysts offering 12-month price forecasts for Astellas Pharma Inc have a median target of 15.37, with a high estimate of 17.57 and a low estimate of 14.10. The median estimate represents a +10.16% increase from the last price of 13.95.
The current consensus among 11 polled investment analysts is to Hold stock in Astellas Pharma Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.